Navigation Links
Estrogen Curbs Appetite: Research

Researchers at Yale School of Medicine have found out that Estrogen regulates the brain's energy metabolism in the same way as the hormone leptin, leading the way to a viable// approach to tackling obesity in people resistant to leptin. Their findings were published in the December 31 online issue of Nature Medicine.

"We found that estrogen suppresses appetite using the same pathways in the brain as the adipose hormone leptin," said lead author Tamas L. Horvath, chair and professor of Comparative Medicine and professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale School of Medicine.

Horvath and his team studied the regulation of obesity in mice with mutations in leptin or estrogen signaling. They analyzed the effect of estrogen on the ability of nerve cells to make new connections in the hypothalamus. They also measured the associated feeding behavior and energy expenditure of the animals.

According to their report, estrogen is a strong regulator of energy metabolism through the brain. They show that while the pathway of estrogen-induced intracellular signaling merges with that of leptin, estrogen's effect on feeding and obesity is independent from leptin or the leptin receptor.

"Impaired estrogen signaling in the brain may be the cause of metabolic changes during menopause," said Horvath. "Brain-selective mimics of estrogen could be a viable approach to tackle obesity in the case of leptin resistance."

In previous studies, Horvath and his team found that that estrogen induces synaptic plasticity in the hypothalamus, so they looked to see whether those alterations by estrogen were in line with the proposed shift in the activity of the hypothalamus.

In future studies, Horvath and his team will analyze brain-specific mimics of estrogen on metabolism, obesity in particular. "Brain-specific estrogen analogs would allow us to take advantage of estradiol's weight reduci
'"/>




Page: 1 2

Related medicine news :

1. Estrogen lowers cancer risk
2. Estrogen Does Not Prevent Recurrent Strokes
3. Herbs With Estrogen Action Aggravate Cancer Risk
4. Osteoarthritis and Estrogen are connected
5. Estrogen Patch is Safer than Pills for Heart
6. Estrogen in Food Reduces Cancer Risk
7. Estrogen Found To Protect the Colon Against Cancer
8. The Side Effects Of Estrogen Therapy
9. The Effects Of Estrogen Therapy
10. A Likely Use For Estrogen Therapy
11. Preventing Colon Cancer With Estrogen
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Estrogen Curbs Appetite Research

Breaking Medicine News(10 mins):Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 2Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 3Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 4Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 5Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 6Health News:Buffalo Personal Injury Lawyers Cellino & Barnes Donate $1M to UB School of Law, Appear on Cover of School's Philanthropy Magazine 2Health News:Wellness Manufacturer Wins Two 2009 American Spa Awards 2Health News:The Flag Company, Inc.'s Recently Released “Feel Good” Light Lenses Grows Into Its Own Website 2Health News:The Flag Company, Inc.'s Recently Released “Feel Good” Light Lenses Grows Into Its Own Website 3Health News:NVHR Offers Congressman Hank Johnson Support & Encouragement as He Battles Chronic Hepatitis C Virus 2
Breaking Medicine Technology:ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 2ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 3ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 4ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 5ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 6ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 7FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Mathematical modeling predicts response to Herceptin 52980 1Mathematical modeling predicts response to Herceptin 52980 2Ongoing Study Shows That Endovascular Therapy is Associated With High Cure Rate for Childhood Eye Cancer 52979 1Ongoing Study Shows That Endovascular Therapy is Associated With High Cure Rate for Childhood Eye Cancer 52979 2Ongoing Study Shows That Endovascular Therapy is Associated With High Cure Rate for Childhood Eye Cancer 52979 3Ongoing Study Shows That Endovascular Therapy is Associated With High Cure Rate for Childhood Eye Cancer 52979 4The CLASS Act 3A Retirement In Security 52977 1The CLASS Act 3A Retirement In Security 52977 2